PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy

PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy

Background: A new therapeutic avenue combining Durvalumab with cisplatin-pemetrexed (Durva-CP) has delivered a promising outcome for previously untreated patients with unresectable malignant pleural mesothelioma (MPM) in clinical trials. However, the limited patient response to Durva-CP needs predic...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrei Gurau, Suguru Yamauchi, Kaitlyn Ecoff, Kristen P. Rodgers, James R. Eshleman, Charles Conover Talbot Jr, Peng Huang, Joshua Choi, Patrick M. Forde, Valsamo Anagnostou, Malcolm Brock, Yuping Mei
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2025-06-01
Series:Non-coding RNA Research
Subjects:
PD-L1
pfeRNA
MPM
Durvalumab
Pemetrexed
Cisplatin
Online Access:http://www.sciencedirect.com/science/article/pii/S2468054025000253
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items